Modulation of 11β-Hydroxysteroid Dehydrogenase Isozymes by Growth Hormone and Insulin-Like Growth Factor: In Vivo and In Vitro Studies1
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The interconversion of hormonally active cortisol (F) and inactive cortisone (E) is catalyzed by two isozymes of 11β-hydroxysteroid dehydrogenase (11βHSD), an oxo-reductase converting E to F (11βHSD1) and a dehydrogenase (11βHSD2) converting F to E. 11βHSD1 is important in mediating glucocorticoid-regulated glucose homeostasis and regional adipocyte differentiation. Earlier studies conducted with GH-deficient subjects treated with replacement GH suggested that GH may modulate 11βHSD1 activity. In 7 acromegalic subjects withdrawing from medical therapy (Sandostatin-LAR; 20–40 mg/month for at least 12 months), GH rose from 7.1 ± 1.5 to 17.5 ± 4.3 mU/L (mean ± se), and insulin-like growth factor I (IGF-I) rose from 43.0 ± 8.8 to 82.1 ± 13.7 nmol/L (both P < 0.05) 4 months after treatment. There was a significant alteration in the normal set-point of F to E interconversion toward E. The fall in the urinary tetrahydrocortisols/tetrahydocortisone ratio (THF+allo-THF/THE; 0.82 ± 0.06 to 0.60 ± 0.06; P < 0.02) but unaltered urinary free F/urinary free E ratio (a marker for 11βHSD2 activity) suggested that this was due to inhibition of 11βHSD1 activity. An inverse correlation between GH and the THF+allo-THF/THE ratio was observed (r = −0.422; P < 0.05). Conversely, in 12 acromegalic patients treated by transsphenoidal surgery (GH falling from 124 ± 49.2 to 29.3 ± 15.4 mU/L; P < 0.01), the THF+allo-THF/THE ratio rose from 0.53 ± 0.06 to 0.63 ± 0.07 (P < 0.05). Patients from either group who failed to demonstrate a change in GH levels showed no change in the THF+allo-THF/THE ratio. In vitro studies conducted on cells stably transfected with either the human 11βHSD1 or 11βHSD2 complementary DNA and primary cultures of human omental adipose stromal cells expressing only the 11βHSD1 isozyme indicated a dose-dependent inhibition of 11βHSD1 oxo-reductase activity with IGF-I, but not GH. Neither IGF-I nor GH had any effect on 11βHSD2 activity. GH, through an IGF-I-mediated effect, inhibits 11βHSD1 activity. This reduction in E to F conversion will increase the MCR of F, and care should be taken to monitor the adequacy of function of the hypothalamo-pituitary-adrenal axis in acromegalic subjects and in GH-deficient, hypopituitary patients commencing replacement GH therapy. Conversely, enhanced E to F conversion occurs with a reduction in GH levels; in liver and adipose tissue this would result in increased hepatic glucose output and visceral adiposity, suggesting that part of the phenotype currently attributable to adult GH deficiency may be an indirect consequence of its effect on tissue F metabolism via 11βHSD1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 4×
“Our earlier studies have demonstrated that 11bHSD1, but not 11bHSD2, is expressed in adipose tissue ( 7 ).”
BackgroundMethodSelf-citationTannin, G. M., Agarwal, A. K., Monder, C., New, M. I., & White, P. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55351-5 · Cited by 436
Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man
Palermo, M., Shackleton, C. H. L., Mantero, F., & Stewart, P. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00853.x · Cited by 276 · cited 2×
“The assessment of activity of these 11bHSD isozymes in man can be inferred from a 24-h urinary steroid metabolite profile by measuring the excretion of free and A ring-reduced F and E metabolites (14, 15 ).”
BackgroundSelf-citationMass spectrometry in the diagnosis of steroid-related disorders and in hypertension research
Shackleton, C. H. L. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90132-g · Cited by 247 · cited 1×
“The assessment of activity of these 11bHSD isozymes in man can be inferred from a 24-h urinary steroid metabolite profile by measuring the excretion of free and A ring-reduced F and E metabolites ( 14 , 15).”
BackgroundGelding, S. V., Taylor, N. F., Wood, P. J., Noonan, K., Weaver, J. U., Wood, D. F., & Monson, J. P. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.3641180.x · Cited by 124
Self-citation
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“In vitro studies show that 11 -HSD-1 oxoreductase activity is inhibited by IGF-I, but not GH (379).”
BackgroundEffects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Møller, N., & Jørgensen, J. O. L. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0027 · Cited by 1,039
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
Self-citation11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Self-citation
Metadata
- Authors
- Moore, J. S., Monson, J. P., Kaltsas, G., Putignano, P., Wood, P. J., Sheppard, M. C., Besser, G. M., Taylor, N. F., & Stewart, P. M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-11-01
- Volume
- 84
- Issue
- 11
- Pages
- 4172-4177
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2073486532
- Cited by
- 154
- References
- 6
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of 11β-Hydroxysteroid Dehydrogenase Isozymes by Growth Hormone and Insulin-Like Growth Factor: In Vivo and In Vitro Studies1. https://app.cochat.ai/papers/10.1210/jcem.84.11.6108
- The paper
- Moore, J. S., Monson, J. P., Kaltsas, G., Putignano, P., Wood, P. J., Sheppard, M. C., Besser, G. M., Taylor, N. F., & Stewart, P. M. (1999). Modulation of 11β-Hydroxysteroid Dehydrogenase Isozymes by Growth Hormone and Insulin-Like Growth Factor: In Vivo and In Vitro Studies1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.84.11.6108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.